Abstract 205P
Background
The real-life experience of radium-223 (Ra223) in metastatic castration-resistant prostate cancer (mCRPC) in Asia is limited. In recent ERA223 study, the post-treatment osteoporotic fracture risk was unexpectedly found elevated when Ra223 was given in addition to abiraterone/prednisone in mCRPC, raising a concern of long-term bone safety with Ra223.
Methods
Hospital records of consecutive patients with mCRPC treated with Ra223 in 5 Hong Kong public hospitals from Nov 2015 to Oct 2018 were retrieved for the analysis of treatment pattern and clinical outcomes.
Results
We identified 42 men with bony mCRPC (median age: 73; 78.6% ECOG PS 0/1; 61.9% with bone pain; 50% lymphadenopathy; 14.3% visceral metastases) who received at least 1 dose of Ra233 (median 6, IRQ: 4-6). Median follow-up was 8.8 months. Ra223 was administered at a median of 3rd line setting (IQR: 2nd to 4th line) with 88.1% and 35.7% having prior androgen-receptor axis-targeted agents (ARTAs, i.e. abiraterone and enzalutamide) and docetaxel. Ra223 was used concomitantly with ARTAs and bone health agents at 23.8% and 45.2%, respectively. 64.5% of patients had subsequent therapies (16.7% chemotherapy; 42.9% ARTAs). Median time to PSA progression was 3.6 months (IQR: 3.5-4.5) and 48.6% (18/37) had 30% drop of ALP after 3rd injection. 26.9% (7/26) with bone pain requiring analgesics had symptomatic improvement but 15% had worsened pain. 66.7% of patients were free from symptomatic skeletal event (SSE), with 6-month and 1-year SSE rates being 11.9% and 26.2%. The median OS was 18.2 months (95%CI: 4.6-31.9) and was longer for patients who received >4 injections (27.7 vs 7.8 months, p = 0.015). The most common AEs were anemia (67%), fatigue (36%), bone pain (33%), thrombocytopenia (26%) and neutropenia (19%). Treatment discontinuation due to AEs was 8%. Non-osteoporotic fracture was seen in 3 patients (2 pathological and 1 traumatic).
Conclusions
Later line use of Ra223 was a common real-life practice. Efficacy and tolerability with Ra223 remains favorable in heavily-pretreated mCRPC, despite higher rate of hematological AE was seen. With nearly ¼ patients with concomitant ARTAs, osteoporotic fracture was not seen in this cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract